News and Media

The Company reports about growth in sales of antibiotics and respiratory drugs   Tchaikapharma High Quality Medicines Inc. reports revenue growth and profit more than doubling by the end of 2021.  The company’s net profit at the end of the last quarter for 2021 amounted to BGN 1,667 million compared to BGN 604 thousand at […]

The newest medicinal product to receive a Marketing Authorization from the Bulgarian Drug Agency is:   TromBay 100 mg tablets (with active ingredient cilostazol).   Its actions are several and include dilating certain blood vessels and reducing the clotting activity (agglutination) of certain blood cells, called platelets, in blood vessels.   The medicinal product is […]

SOFIX was one of the most successful stock indices in 2021. The indicator outlined a successful trading on the Bulgarian Stock Exchange for both investors and public companies. For the twelve months of last year, the “blue chip” index grew by 42.23% to 635.68 points, showed a study by the newspaper. “Banker”. The main index […]

Tchaikapharma High Quality Medicines obtained marketing authorisations for the Republic of Kosovo for the medicinal products Bilamcar 8 mg/5 mg; 16 mg/5 mg hard capsules and Ceftriaxon-Tchaikapharma 1 g; 2 g powder for solution for injection/infusion. The first deliveries are planned for early 2022.   Thus, the number of registered products of the company in […]

The latest medicinal products to receive Marketing Authorization from the BDA and expand Tchaikapharma’s rich and diverse portfolio are:   – Tamaira Plus 5 mg/5 mg/12.5 mg; 5 mg/5 mg/25 mg; 10 mg/5 mg/25 mg hard capsules (with APIs ramipril, amlodipine and hydrochlorothiazide).   The medicinal product is indicated for the treatment of high blood […]